Robert Hite

- Developed and delivered Vara's medical brand and commercialization strategy - Developed and delivered company re-brand including shared vision, brand book, website and public relations campaign - Orchestrated clinical development activities, including 5 peer-reviewed publications, high-profile academic collaborations and innovative prospective clinical study - Leveraged professional network to establish new relationships with international luminaries in the mammography domain

Leveraging over 20 years of corporate healthcare experience in diverse international markets to consult innovative medical imaging startups. - Arterys Inc (San Francisco): Developed go-to-market strategy for market entry in Germany, Austria & Switzerland for US-based startup. Arterys is developing a suite of applications for radiologists via its cloud-based, web-enabled AI medical imaging SaaS platform.

• Established and led team of global marketing professionals (Berlin and Pittsburgh) • Revitalized global marketing of an established CT/x-ray contrast medium, resulting in short-term sales turnaround and significant long-term growth • Created long-term CT portfolio roadmap (contrast media, medical device and software) as part of holistic portfolio review for development projects based on customer-centric vision

• Led large team of sales, marketing and technical service professionals, served as officer (Prokura) of Bayer Vital GmbH and member of Radiology & Interventional European Leadership Team; reported to Radiology Head of Region Europe • Grew topline while achieving internal/external benchmark profitability and high employee engagement • Led successful local integration of Bayer’s German Diagnostic Imaging business with MEDRAD Medizintechnik GmbH forming new combined business

• Led formation of new business unit (Specialized Therapeutics) at Schering Healthcare Ltd. as a result of large local reorganization in 2005 to align to global business unit structure, reported directly to UK Managing Director • Orchestrated business turnaround and re-established Betaferon® (approved in 2002) as major player among healthcare professionals and patient organizations after several years of negative product perception

• Led team of marketing professionals; reported to Japan Head of Business Unit Specialized Therapeutics • Re-invigorated all aspects of marketing and sales excellence of Betaferon® • Created public relations campaign with external agency to increase awareness of multiple sclerosis and Betaferon® in Japan • Orchestrated first Pan-Asian MS symposium for neurologists in 2003; which evolved into Pan-Asian Committee for the Treatment and Research in Multiple Sclerosis (PACTRIMS) in 2007

Provided medical guidance within a commercial context in the field of gynecology; supported Phase IV and investigator-sponsored clinical trials. Established the provision of a medical information service including comprehensive sales training for the launch of Yasmin, a novel oral contraceptive. Created and implemented a successful, accredited Continuing Medical Education program for German gynecologists.

Germany